Universal allogeneic anti-CD19/BCMA CAR T-cells
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 1 |
| 49 | Systemic lupus erythematosus | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
| 61 | Autoimmune hemolytic anemia | 2 |
11. Myasthenia gravis
Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. Systemic lupus erythematosus
Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
51. Scleroderma
Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
61. Autoimmune hemolytic anemia
Clinical trials : 218 / Drugs : 186 - (DrugBank : 42) / Drug target genes : 27 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
